

**Participant at the Midcap Event in Paris on September 21<sup>st</sup> and 22<sup>nd</sup> 2009**

**Nantes (France) – September 14, 2009:** VIVALIS (NYSE Euronext Paris: VLS), a biopharmaceutical company that provides the pharmaceutical industry with innovative cell-based solutions for the manufacture of vaccines and proteins and develops drugs to prevent and treat viral diseases, will be participating to the Midcap Event on September 21<sup>st</sup> and 22<sup>nd</sup>, 2009. This forum will take place at Palais Brongniart, 19 rue Notre-Dame des Victoires, 75002 Paris, France.

VIVALIS has recorded very solid commercial and scientific performances since the beginning of the year, with the signature of 7 additional licences to reach a total of 27 licences signed in both vaccines and proteins applications. At the same time, VIVALIS remains in a solid financial situation with 24.6 million euros in cash and cash equivalent at June 30, 2009.

VIVALIS will be located at the Arkeon Finance stand. During these two days, fund managers will have the opportunity to exchange with Franck Grimaud, CEO, and Philippe Rousseau, CFO on the performance to date as well as its strategy and perspectives.

\*\*\*\*\*

**About the EB66<sup>®</sup> line**

The EB66<sup>®</sup> cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics such as long-term genetic stability, immortality and cell growth to high cell densities in suspension in a serum-free medium (>20 millions cells/mL).

The BMF (Biologics Master File) for the registration of the EB66<sup>®</sup> cell line with the FDA (U.S. Food and Drug Administration) was filed on June 27, 2008.

The EB66<sup>®</sup> cell line is currently used or being tested by 75% of the major players in vaccines. VIVALIS has furthermore demonstrated that the EB66<sup>®</sup> cell line can be easily genetically modified, permitting the expression of recombinant proteins of potential interest. Moreover the glycosylation profile of monoclonal antibodies produced through EB66<sup>®</sup> cell lines is similar to the glycosylation profiles of human monoclonal antibodies with the added benefit of being distinguished by reduced fucose content. This latter characteristic is known to be associated with a higher level of antibody cytotoxic activity, particularly useful in the treatment of cancer cells.

**About VIVALIS ([www.vivalis.com](http://www.vivalis.com))**

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66<sup>®</sup> cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines. Vivalis receives upfront fees, milestone payments and royalties on its licensees' net sales.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EB66<sup>®</sup> cell line for the production of recombinant proteins to biotechnology and

pharmaceutical companies. Vivalis receives upfront fees, milestone payments and royalties on its licensees' net sales.

3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, CSL, Kaketsuken, Merial, Intervet, SAFB Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

#### VIVALIS

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

**Included in NYSE Euronext's Next Biotech index**



#### Contacts

##### **VIVALIS**

Franck Grimaud, CEO

Email: [investors@vivalis.com](mailto:investors@vivalis.com)

##### **NewCap**

Financial communications agency

Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91

Email: [vivalis@newcap.fr](mailto:vivalis@newcap.fr)